Consortia of living bacteria useful for treatment of microbiome dysbiosis
US11219649B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 12, 2018 |
| Grant date | Jan 11, 2022 |
| Priority date | — |
| Expiry date | Oct 20, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel compositions comprising specific consortia of living bacteria strains; to the manufacturing of such compositions, particularly by co-cultivation; and to the use of such compositions in pharmaceutical applications, such as the treatment of diseases associated with intestinal microbiota dysbiosis, particularly intestinal infections such as CDI (Clostridium difficile infection) and IBD (Inflammatory bowel diseases). When compared to the traditional FMT therapy () the inventive compositions () are more efficient and safer as demonstrated on an acute colitis model and therefore more appropriate for therapeutic use.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.